Terminated PHASE4 INTERVENTIONAL 1-arm NCT00664430

Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects

Sponsor: Abbott

Conditions Dialysis Secondary Hyperparathyroidism

Updated 9 times since 2017 Last updated: Jan 18, 2012 Started: Jan 31, 2009 Primary completion: Jun 30, 2009 Completion: Jun 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Low enrollment rate

Other terminated trials from Abbott

See all terminations from Abbott

Other Dialysis trials with similar outcome

NCT03517553 · Phase NA · Nov 2014

Browse all Dialysis trials

Listed as NCT00664430, this PHASE4 trial focuses on Dialysis and Secondary Hyperparathyroidism and remains terminated or withdrawn. Sponsored by Abbott, it has been updated 9 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE4
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE4
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE4

▶ Show 4 earlier versions

Dec 2021 — Dec 2022 [monthly]

Terminated PHASE4
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE4
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE4
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE4

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott
Statistika Consultoria Ltda

Data source: Abbott

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• São Paulo, Brazil